| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_63d308de47aca27fde3c30d3f02aa4e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96c75027c33f6d65866de8f1ce995d96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6ae22bf3059bd4902faa23196388c8e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ddbd95714a9ccf2790cf57372cbdf1bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5b5ecfb7b9df4ca507552489522270a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-00 |
| filingDate |
2007-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ed95bd59fb370069d2a5f3b2eb98f88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d9e4739810e5d66b181d071d820d905
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31e9f2ae6933f3bae59eb704f53eba63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6460e62088ad299eb9175a09028d7612
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4716caa777afd49651fc81a82c486abd |
| publicationDate |
2009-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009136503-A1 |
| titleOfInvention |
Trail receptor-binding agents and uses of the same |
| abstract |
This invention relates generally to the preparation of TRAIL receptor-binding agents and uses of the same. In particular, the present invention relates to the preparation of anti-TRAIL receptor antibodies which recognize a common antigen determinant (i.e., epitope) shared by TRAIL-R1 and TRAIL-R2 receptors and their use for TRAIL receptor detection and modulation of TRAIL receptor-mediated function. The TRAIL receptor-binding agents are useful to induce apoptosis in human cancer cells. These targets may either express one or both TRAIL-R1 or TRAIL-R2. The invention provides for the use of the TRAIL receptor-binding agents of the invention in cancer therapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020243616-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019211472-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018161450-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014206025-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10918739-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018146317-A1 |
| priorityDate |
2006-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |